{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:26:07Z","timestamp":1788305167068,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00277-019-03739-2","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T22:02:16Z","timestamp":1561500136000},"page":"2139-2150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed\/refractory multiple myeloma"],"prefix":"10.1007","volume":"98","author":[{"given":"Ivan","family":"Spicka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique M.","family":"Ocio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather E.","family":"Oakervee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond H.","family":"Banh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"D\u2019Rozario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Extremera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Kahatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo M.","family":"Carella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Meuleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"H\u00e1jek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argiris","family":"Symeonidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cannell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,25]]},"reference":[{"issue":"1","key":"3739_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/leu.2011.196","volume":"26","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Blade J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG, International Myeloma Working G (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26(1):149\u2013157. \n                    https:\/\/doi.org\/10.1038\/leu.2011.196","journal-title":"Leukemia"},{"issue":"2","key":"3739_CR2","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/sj.leu.2405016","volume":"22","author":"KC Anderson","year":"2008","unstructured":"Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P, Myeloma AFPCEM (2008) Clinically relevant end points and new drug approvals for myeloma. Leukemia 22(2):231\u2013239. \n                    https:\/\/doi.org\/10.1038\/sj.leu.2405016","journal-title":"Leukemia"},{"issue":"1","key":"3739_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1074\/jbc.M201010200","volume":"278","author":"A Cuadrado","year":"2003","unstructured":"Cuadrado A, Garcia-Fernandez LF, Gonzalez L, Suarez Y, Losada A, Alcaide V, Martinez T, Fernandez-Sousa JM, Sanchez-Puelles JM, Munoz A (2003) Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. J Biol Chem 278(1):241\u2013250. \n                    https:\/\/doi.org\/10.1074\/jbc.M201010200","journal-title":"J Biol Chem"},{"issue":"27","key":"3739_CR4","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1038\/sj.onc.1207636","volume":"23","author":"A Cuadrado","year":"2004","unstructured":"Cuadrado A, Gonzalez L, Suarez Y, Martinez T, Munoz A (2004) JNK activation is critical for Aplidin-induced apoptosis. Oncogene 23(27):4673\u20134680. \n                    https:\/\/doi.org\/10.1038\/sj.onc.1207636","journal-title":"Oncogene"},{"key":"3739_CR5","doi-asserted-by":"publisher","first-page":"35100","DOI":"10.1038\/srep35100","volume":"6","author":"A Losada","year":"2016","unstructured":"Losada A, Munoz-Alonso MJ, Garcia C, Sanchez-Murcia PA, Martinez-Leal JF, Dominguez JM, Lillo MP, Gago F, Galmarini CM (2016) Translation elongation factor eEF1A2 is a novel anticancer target for the marine natural product plitidepsin. Sci Rep 6:35100. \n                    https:\/\/doi.org\/10.1038\/srep35100","journal-title":"Sci Rep"},{"issue":"13","key":"3739_CR6","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.1158\/0008-5472.CAN-07-5725","volume":"68","author":"CS Mitsiades","year":"2008","unstructured":"Mitsiades CS, Ocio EM, Pandiella A, Maiso P, Gajate C, Garayoa M, Vilanova D, Montero JC, Mitsiades N, McMullan CJ, Munshi NC, Hideshima T, Chauhan D, Aviles P, Otero G, Faircloth G, Mateos MV, Richardson PG, Mollinedo F, San-Miguel JF, Anderson KC (2008) Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res 68(13):5216\u20135225. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-5725","journal-title":"Cancer Res"},{"issue":"6","key":"3739_CR7","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/bjc.1998.570","volume":"78","author":"H Depenbrock","year":"1998","unstructured":"Depenbrock H, Peter R, Faircloth GT, Manzanares I, Jimeno J, Hanauske AR (1998) In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br J Cancer 78(6):739\u2013744","journal-title":"Br J Cancer"},{"issue":"12","key":"3739_CR8","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1158\/1078-0432.CCR-10-0469","volume":"16","author":"MV Mateos","year":"2010","unstructured":"Mateos MV, Cibeira MT, Richardson PG, Prosper F, Oriol A, de la Rubia J, Lahuerta JJ, Garcia-Sanz R, Extremera S, Szyldergemajn S, Corrado C, Singer H, Mitsiades CS, Anderson KC, Blade J, San Miguel J (2010) Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin Cancer Res 16(12):3260\u20133269. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0469","journal-title":"Clin Cancer Res"},{"issue":"Suppl 6","key":"3739_CR9","doi-asserted-by":"publisher","first-page":"vi133","DOI":"10.1093\/annonc\/mdt297","volume":"24","author":"P Moreau","year":"2013","unstructured":"Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, Dreyling M, Group EGW (2013) Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi133\u2013vi137. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdt297","journal-title":"Ann Oncol"},{"issue":"18","key":"3739_CR10","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J, International Myeloma Workshop Consensus P (2011) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117(18):4691\u20134695. \n                    https:\/\/doi.org\/10.1182\/blood-2010-10-299487","journal-title":"Blood"},{"issue":"3","key":"3739_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/0272989X13520192","volume":"34","author":"NR Latimer","year":"2014","unstructured":"Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL, Campbell MJ (2014) Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations. Med Decis Mak 34(3):387\u2013402. \n                    https:\/\/doi.org\/10.1177\/0272989X13520192","journal-title":"Med Decis Mak"},{"issue":"6","key":"3739_CR12","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/bjh.13227","volume":"168","author":"G Morgan","year":"2015","unstructured":"Morgan G, Palumbo A, Dhanasiri S, Lee D, Weisel K, Facon T, Delforge M, Oriol A, Zaki M, Yu X, Sternas L, Jacques C, Akehurst R, Offner F, Dimopoulos MA (2015) Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone. Br J Haematol 168(6):820\u2013823. \n                    https:\/\/doi.org\/10.1111\/bjh.13227","journal-title":"Br J Haematol"},{"issue":"14","key":"3739_CR13","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","volume":"120","author":"DS Siegel","year":"2012","unstructured":"Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S (2012) A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120(14):2817\u20132825. \n                    https:\/\/doi.org\/10.1182\/blood-2012-05-425934","journal-title":"Blood"},{"issue":"10027","key":"3739_CR14","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","volume":"387","author":"S Lonial","year":"2016","unstructured":"Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Blade J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM (2016) Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387(10027):1551\u20131560. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)01120-4","journal-title":"Lancet"},{"issue":"11","key":"3739_CR15","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"J San Miguel","year":"2013","unstructured":"San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 14(11):1055\u20131066. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(13)70380-2","journal-title":"Lancet Oncol"},{"issue":"21","key":"3739_CR16","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foa R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD, Multiple Myeloma Study I (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357(21):2123\u20132132. \n                    https:\/\/doi.org\/10.1056\/NEJMoa070594","journal-title":"N Engl J Med"},{"issue":"24","key":"3739_CR17","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352(24):2487\u20132498. \n                    https:\/\/doi.org\/10.1056\/NEJMoa043445","journal-title":"N Engl J Med"},{"issue":"14","key":"3739_CR18","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/blood-2013-01-481325","volume":"122","author":"PG Richardson","year":"2013","unstructured":"Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, Lonial S (2013) PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 122(14):2331\u20132337. \n                    https:\/\/doi.org\/10.1182\/blood-2013-01-481325","journal-title":"Blood"},{"issue":"6","key":"3739_CR19","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood-2015-09-665018","volume":"127","author":"PG Richardson","year":"2016","unstructured":"Richardson PG, Hungria VTM, Yoon S-S, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa B-R, Corrado C, Binlich F, San-Miguel JF (2016) Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood 127(6):713\u2013721. \n                    https:\/\/doi.org\/10.1182\/blood-2015-09-665018","journal-title":"Blood"},{"issue":"5","key":"3739_CR20","doi-asserted-by":"publisher","first-page":"e10755","DOI":"10.1371\/journal.pone.0010755","volume":"5","author":"Z Li","year":"2010","unstructured":"Li Z, Qi CF, Shin DM, Zingone A, Newbery HJ, Kovalchuk AL, Abbott CM, Morse HC 3rd (2010) Eef1a2 promotes cell growth, inhibits apoptosis and activates JAK\/STAT and AKT signaling in mouse plasmacytomas. PLoS One 5(5):e10755. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0010755","journal-title":"PLoS One"},{"key":"3739_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2217\/fon-2018-0492","volume":"15","author":"M Leisch","year":"2018","unstructured":"Leisch M, Egle A, Greil R (2018) Plitidepsin: a potential new treatment for relapsed\/refractory multiple myeloma. Future Oncol 15:109\u2013120. \n                    https:\/\/doi.org\/10.2217\/fon-2018-0492","journal-title":"Future Oncol"},{"issue":"2","key":"3739_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/jcb.20969","volume":"100","author":"R Chang","year":"2007","unstructured":"Chang R, Wang E (2007) Mouse translation elongation factor eEF1A-2 interacts with Prdx-I to protect cells against apoptotic death induced by oxidative stress. J Cell Biochem 100(2):267\u2013278. \n                    https:\/\/doi.org\/10.1002\/jcb.20969","journal-title":"J Cell Biochem"},{"issue":"1","key":"3739_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2014.05.045","volume":"450","author":"Y Sun","year":"2014","unstructured":"Sun Y, Du C, Wang B, Zhang Y, Liu X, Ren G (2014) Up-regulation of eEF1A2 promotes proliferation and inhibits apoptosis in prostate cancer. Biochem Biophys Res Commun 450(1):1\u20136. \n                    https:\/\/doi.org\/10.1016\/j.bbrc.2014.05.045","journal-title":"Biochem Biophys Res Commun"},{"issue":"21","key":"3739_CR24","doi-asserted-by":"publisher","first-page":"18545","DOI":"10.1074\/jbc.M201022200","volume":"277","author":"Y Hotokezaka","year":"2002","unstructured":"Hotokezaka Y, Tobben U, Hotokezaka H, Van Leyen K, Beatrix B, Smith DH, Nakamura T, Wiedmann M (2002) Interaction of the eukaryotic elongation factor 1A with newly synthesized polypeptides. J Biol Chem 277(21):18545\u201318551. \n                    https:\/\/doi.org\/10.1074\/jbc.M201022200","journal-title":"J Biol Chem"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03739-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03739-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03739-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T23:12:12Z","timestamp":1592953932000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03739-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,25]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["3739"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03739-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,25]]},"assertion":[{"value":"9 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"IS has honoraria (Amgen, Takeda, Janssen-Cilag, BMS, Celgene); consulting or advisory role (Amgen, Takeda, Janssen-Cilag, Celgene); speakers\u2019 bureau (Amgen, BMS Celgene, Jansen-Cilag); and travel, accommodation, or expenses (Celgene, Amgen, Jansen-Cilag) to disclose.EMO has honoraria (Novartis, Takeda, Celgene, Amgen, BMS, Janssen); consulting or advisory role (Novartis, Takeda, Celgene, AbbVie, Pharma Mar, Seattle Genetics, Amgen); speakers\u2019 bureau (Takeda); research funding to his institution (Celgene, Amgen, Array, Mundipharma, Sanofi, MSD); patents, royalties, or other intellectual properties (Pharma Mar, Mundipharma, IDP); and travel, accommodation, or expenses (Celgene, Janssen, Takeda) to disclose.HEO has a leadership role (Vertex, Astenas); stock ownership (Vertex); research funding (BMS, Pharma Mar); and travel, accommodation, or expenses (Novartis) to disclose.RG has honoraria (Celgene, Roche, Merck, Takeda, Astra Zeneca, Novartis, Amgen, BMS, MSD, Sandoz); consulting or advisory role (Celgene, Novartis, Roche, BMS, Takeda, AbbVie, Astra Zeneca, Janssen); research funding (Celgene, Roche, Merck, Takeda, Astra Zeneca, Novartis, Amgen, BMS, MSD, Sandoz); and travel, accommodation, or expenses (Roche, Amgen, Janssen, Astra Zeneca) to disclose.RHB has a consulting or advisory role (Specialised Therapeutics, Pharma Mar, BMS); research funding (Acerta, Pharma Mar, Celgene, Gilead, Novotech, Pharmacyclics, Roche); and travel, accommodation, or expenses (Roche, Janssen) to disclose.JMDR has honoraria (Alexion, Roche); consulting or advisory role (Alexion, Roche); and travel, accommodation, or expenses (Pharma Mar, Alexion) to disclose.Meletios A. Dimopoulos has honoraria (Amgen, Takeda, Janssen, Celgene, BMS) to disclose.SM, SE, CK, and VA are employees of Pharma Mar S.A.SE, CK, and VA have stock ownerships (Pharma Mar).RH has honoraria (Amgen, BMS, Takeda, Celgene, Janssen); consulting or advisory role (Amgen, BMS, Takeda, Celgene, Janssen); research funding to his institution (Takeda, Novartis, Amgen, Janssen, Celgene); travel, accommodation, or expenses (Amgen, BMS, Celgene, Janssen, Takeda) to disclose.AS has honoraria (AbbVie, Amgen, Celgene, Janssen, Gilead, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda, WinMedica); consulting or advisory role (AbbVie, Amgen, Celgene, Janssen, Gilead, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda); speakers\u2019 bureau (AbbVie, Amgen, Celgene, Janssen, Gilead, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda, WinMedica); research funding to his institution (AbbVie, Actelion, Alexion, Amgen, Astellas, Bayer, Bristol, Celgene, Demo\/ApoPharma, Enorasis, Faran, Gilead, Janssen, MSD, Novartis, Pharmaten, Pfizer, Rafarm, Roche, Sanofi, Takeda, Teva, Vianex, WinMedica); and travel, accommodation, or expenses (AbbVie, Amgen, Celgene, Janssen, Gilead, Roche, Sanofi, Takeda) to disclose.PC has travel, accommodations, or expenses (Amgen, Roche, BMS\u2014conference attendance sponsorship) to disclose.HL has a consulting or advisory role (Pharma Mar); speakers\u2019 bureau (Takeda, Amgen, Celgene, Janssen, BMS); and research funding (Takeda, Amgen) to disclose.PS has honoraria (Janssen, Celgene, Amgen, Takeda); expert testimony (Pharma Mar); and research funding (Janssen, Celgene, Amgen, Takeda) to disclose.MVM has honoraria to disclose from Pharma Mar because of the involvement in advisory boards.All other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}